Work

A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma

Year: 2024

Type: article

Abstract: Interleukin-15 (IL-15) is a member of the 4-alpha-helix bundle family of cytokines that acts through a heterotrimeric receptor causing potent stimulation of NK and T-cell functions [1]. Recombinant...

Source: Leukemia & lymphoma/Leukemia and lymphoma

DOI: 10.1080/10428194.2024.2326847

Authors: Max J. Gordon, Sigrid Dubois, Bonita Bryant, Samuel Ng, Kevin Conlon, Milos D. Miljkovic, Thomas Waldmann, Mark Roschewski

Institutions: National Cancer Institute, National Cancer Institute, Center for Cancer Research, Cartesian Therapeutics, Inc. (United States)

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4392619624

FWCI: 1.048

Cites: 15

Cited by: 4

Related to: 10